Generic Nuvessa Availability
Last updated on Apr 10, 2025.
Nuvessa is a brand name of metronidazole topical, approved by the FDA in the following formulation(s):
NUVESSA (metronidazole - gel;vaginal)
-
Manufacturer: CHEMO RESEARCH SL
Approval date: March 24, 2014
Strength(s): 1.3% [RLD]
Is there a generic version of Nuvessa available?
No. There is currently no therapeutically equivalent version of Nuvessa available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nuvessa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Aqueous-based metronidazole gel formulations
Patent 10,238,634
Issued: March 26, 2019
Inventor(s): Nordsiek Michael T. & Balaji Kodumudi S.
Assignee(s): CHEMO RESEARCH, S.L.The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
Patent expiration dates:
- June 28, 2032✓
- June 28, 2032
-
Aqueous-based metronidazole gel formulations
Patent 10,596,155
Issued: March 24, 2020
Inventor(s): Nordsiek Michael T. & Balaji Kodumudi S.
Assignee(s): CHEMO RESEARCH, S.L.The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
Patent expiration dates:
- June 28, 2032✓
- June 28, 2032
-
Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
Patent 7,893,097
Issued: February 22, 2011
Inventor(s): Yang; Meidong et al.
Assignee(s): Dow Pharmaceutical Sciences, Inc. (Petaluma, CA)The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.
Patent expiration dates:
- February 19, 2028✓
- February 19, 2028
-
Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
Patent 8,658,678
Issued: February 25, 2014
Inventor(s): Yang Meidong & Chen Haigang
Assignee(s): Dow Pharmaceutical Sciences, Inc.The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.
Patent expiration dates:
- June 27, 2028✓
- June 27, 2028
-
Compositions for increasing solubility of azole drug compounds that are poorly soluble in water
Patent 8,877,792
Issued: November 4, 2014
Inventor(s): Yang Meidong & Chen Haigang
Assignee(s): Dow Pharmaceutical Sciences, Inc.The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.
Patent expiration dates:
- February 2, 2028✓
- February 2, 2028
-
High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
Patent 8,946,276
Issued: February 3, 2015
Inventor(s): Nordsiek Michael T. & Balaji Kodumudi S.
Assignee(s): Watson Laboratories, Inc.The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
Patent expiration dates:
- June 28, 2032✓
- June 28, 2032
-
Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations
Patent 9,198,858
Issued: December 1, 2015
Inventor(s): Nordsiek Michael T. & Balaji Kodumudi S.
Assignee(s): Watson Pharmaceuticals, Inc.The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
Patent expiration dates:
- June 28, 2032✓
- June 28, 2032
More about Nuvessa (metronidazole topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (8)
- Side effects
- Dosage information
- During pregnancy
- Drug class: vaginal anti-infectives
- Breastfeeding
- En español
Patient resources
Other brands
MetroGel, MetroGel-Vaginal, MetroCream, Rozex, ... +5 more
Professional resources
Other brands
MetroGel, MetroGel-Vaginal, MetroCream, Noritate, ... +3 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.